Treatment with FTY720 during the induction or effector phase suppresses the development of experimental allergic conjunctivitis in mice

These data demonstrate that FTY720 treatment during the induction phase decreases the absolute number of CD4+ and CD8+ T cells in the spleen and suppresses Th2 cytokine production by splenocytes. This leads to the suppression of EC. FTY720 treatment also suppresses EC when delivered during the effector phase. Thus, FTY720 treatment may be suitable for treating severe forms of vernal keratoconjunctivitis.